Siena Capital LLC purchased a new position in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,668 shares of the company stock, valued at approximately $ 799,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Family CFO Inc bought a new stake in Johnson & Johnson during the 4th quarter worth about $ 26,000. Steward Financial Group LLC bought a new stake in Johnson & Johnson during the 4th quarter worth about $ 34,000. Iron Horse Wealth Management LLC raised its holdings in Johnson & Johnson by 29.9% during the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock worth $ 45,000 after purchasing an additional 61 shares during the last quarter. Gibson Wealth Advisors LLC bought a new stake in Johnson & Johnson during the 4th quarter worth about $ 49,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in Johnson & Johnson by 290.7% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock worth $ 47,000 after purchasing an additional 218 shares during the last quarter. Institutional investors and hedge funds own 68.78% of the company stock.
JNJ has been the subject of several recent research reports. Morgan Stanley dropped their price objective on Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Bank of America assumed coverage on Johnson & Johnson in a research note on Wednesday, March 2nd. They issued a “neutral” rating for the company. Sanford C. Bernstein cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their price target for the company from $ 180.00 to $ 183.00 in a research note on Wednesday, March 16th. Raymond James upped their price target on Johnson & Johnson from $ 195.00 to $ 196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Finally, Credit Suisse Group upped their price target on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $ 190.50.
NYSE JNJ opened at $ 169.46 on Friday. The business has a 50 day simple moving average of $ 178.10 and a 200 day simple moving average of $ 172.79. Johnson & Johnson has a 52-week low of $ 155.72 and a 52-week high of $ 186.69. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The stock has a market cap of $ 445.92 billion, a price-to-earnings ratio of 22.84, a PEG ratio of 3.36 and a beta of 0.66.
Johnson & Johnson (NYSE: JNJ – Get Rating) last posted its earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $ 2.60 by $ 0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business had revenue of $ 23.43 billion during the quarter, compared to analysts’ expectations of $ 23.62 billion. During the same period in the prior year, the business earned $ 2.59 EPS. Johnson & Johnson’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.23 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were given a dividend of $ 1.13 per share. The ex-dividend date was Monday, May 23rd. This represents a $ 4.52 dividend on an annualized basis and a yield of 2.67%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $ 1.06. Johnson & Johnson’s dividend payout ratio is 60.92%.
In other Johnson & Johnson news, insider William Hait sold 29,699 shares of the company stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total transaction of $ 5,452,142.42. Following the completion of the transaction, the insider now owns 80,236 shares of the company stock, valued at approximately $ 14,729,724.88. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $ 173.00, for a total value of $ 6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company stock, valued at approximately $ 12,336,803. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 78,161 shares of company stock valued at $ 13,895,302. Insiders own 0.35% of the company stock.
About Johnson & Johnson: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.